What is CD30 lymphoma?
CD30 is a cell surface receptor expressed in classical Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL), and many other lymphomas to a variable degree. It has been identified as an important therapeutic target in lymphoma.
How do you test for CD30?
Most commonly, CD30 expression is detected and performed by immunohistochemical staining of biopsy samples. Alternatively, flow cytometry analysis has also been developed for fresh tissue and cell aspiration specimens, including peripheral blood and bone marrow aspirate.
What is CD30 test?
CD30 is a member of the tumor necrosis factor receptor (TNF-R) superfamily. Expression of CD30 can also be seen in embryonal carcinomas, malignant melanomas, mesenchymal tumors, and activated T and B lymphocytes and plasma cells.
What is vedotin?
Brentuximab vedotin contains a monoclonal antibody that binds to a protein called CD30, which is found on some lymphoma cells. It also contains an anticancer drug, which may help kill cancer cells. Brentuximab vedotin is a type of antibody-drug conjugate. Also called Adcetris and SGN-35.
Is CD30 a protein?
A protein found on some T cells and B cells (two types of white blood cells). It is a receptor for a protein called tumor necrosis factor, which is involved in cell growth and cell survival. The CD30 protein may be found in higher than normal amounts on some types of cancer cells, including lymphoma cells.
What is the function of CD38 in multiple myeloma?
CD38 is highly and uniformly expressed on multiple myeloma (MM) cells, and at relatively low levels on normal lymphoid and myeloid cells, and in some tissues of nonhematopoietic origin. CD38 is a transmembrane glycoprotein with ectoenzymatic activity, and also functions as a receptor and adhesion molecule.
How are monoclonal antibodies used to treat multiple myeloma?
In addition, drugs with a different mechanism of action, such as the histone deacetylase inhibitor and the monoclonal antibodies (MoAb) targeting SLAMF7 or CD38, are a part of the anti-myeloma armamentarium and are very important for heavily pretreated or double refractory to a PI and IMiD patients.
Is there a cure for multiple myeloma ( MM )?
Multiple myeloma (MM) is the second-most common hematologic malignancy after diffuse large B-cell lymphoma. Despite the improvement in response and survival rates following the introduction of novel therapies, only a few patients are cured, and the majority of MM patients experience several relapses and receive multiple lines of treatment.
Which is an antibody target for the treatment of mm?
The relatively high expression of CD38 on MM cells, in combination with its role as receptor and ectoenzyme, suggested CD38 as a potential therapeutic antibody target for the treatment of MM.